COVID vaccine protection against infection starts fading within a few months, but protection against severe illness lasts longer. On average, effectiveness against symptomatic COVID drops by about 25 percentage points within six months of your last dose. That’s why updated vaccines are recommended annually, with additional doses for people at higher risk.
How Quickly Protection Fades
The sharpest decline happens in the first three to four months. Neutralizing antibodies, the front-line defenders that block the virus from entering your cells, drop steeply after the initial post-vaccination peak. One study tracking antibody levels found that the ability to block viral entry averaged 62% inhibition within the first two months after vaccination, fell to 25% by months two to three, and dropped to about 17% by months three to four. By four to six months, most participants had little detectable neutralizing antibody activity.
That antibody decline translates directly into real-world effectiveness. A large meta-analysis published in The Lancet found that protection against symptomatic COVID decreased by roughly 25 percentage points in the general population and by 32 percentage points in older adults between one month and six months after the final dose. Protection against infection of any kind (including cases without symptoms) dropped by about 21 percentage points over the same window.
Protection Against Hospitalization Holds Up Better
Even as your antibody levels fall, your immune system retains deeper layers of defense. Memory B cells and T cells, which take longer to activate but can mount a powerful response once infection takes hold, persist for at least eight to nine months after exposure to the virus. These cells don’t prevent you from catching COVID, but they help your body fight it off before it becomes dangerous. Studies of recovered COVID patients found that T cell responses lasted up to a year, even in people whose antibodies had already declined below detectable levels.
This is why vaccine effectiveness against hospitalization and death consistently outperforms effectiveness against mild infection. The immune memory that prevents severe disease is more durable than the circulating antibodies that block infection entirely.
What the Latest Vaccine Data Shows
The 2024-2025 updated vaccine, which targets the JN.1 Omicron sublineage and its descendants (including KP.3 and XEC, which together made up over 70% of circulating strains during the study period), provides moderate but meaningful protection. CDC data from September 2024 through January 2025 found that for adults 18 and older, the updated vaccine reduced COVID-related emergency department and urgent care visits by 33% during the first four months. That effectiveness held fairly steady, measuring 36% in the first two months and 30% during months two through four.
For adults 65 and older without immune-compromising conditions, protection against hospitalization was stronger: about 45-46% during the first four months after vaccination. For older adults with weakened immune systems, that figure was 40%. These numbers reflect a snapshot relatively early after vaccination. Protection is expected to continue declining beyond that four-month window, consistent with the waning patterns seen with earlier formulations.
Why Older Adults Lose Protection Faster
Age is one of the strongest predictors of how quickly vaccine protection fades. Older adults generate weaker immune responses from the start and lose them faster. Research from The Journal of Infectious Diseases found that 14% of older adults failed to develop detectable virus-neutralizing activity even at peak immunity, one month after their second dose. Two months later, that figure jumped to 44%. By comparison, 98% of younger healthcare workers had strong neutralizing responses at the one-month mark.
Every decade of older age was associated with measurably lower antibody responses after both the first and second doses. Chronic health conditions compounded the problem, with a higher number of conditions linked to weaker antibody levels. This isn’t just an academic distinction: it means an 80-year-old with multiple health issues may have substantially less protection three months after vaccination than a healthy 40-year-old at the same time point.
Hybrid Immunity Lasts Longer
If you’ve had both a COVID infection and vaccination, your immune protection is stronger and more durable than either one alone. This combination, called hybrid immunity, consistently produced the lowest reinfection rates across multiple waves of the pandemic, including during Omicron. People with hybrid immunity had fewer infections than those who were only vaccinated, and fewer than those who had only been previously infected.
During the Delta wave, people with a prior infection who remained unvaccinated actually had lower infection rates than vaccinated people who had never been infected. But the hybrid immunity group outperformed both. This advantage persisted even as new variants emerged, though infection rates rose across all groups during the Omicron period. The takeaway is that vaccination after infection (or infection after vaccination) builds a broader, more resilient immune response than either event on its own.
Current Recommendations for Timing
For most adults, one dose of the updated 2024-2025 COVID vaccine is recommended each year. But for people 65 and older and those with moderate to severe immune compromise, a second dose is recommended six months after the first. The minimum interval between doses is two months, allowing flexibility for people heading into a high-risk period like surgery, travel, or a seasonal surge.
People with significant immune compromise may receive three or more doses of the current vaccine in a single season, based on individual risk. This reflects the reality that their immune systems generate weaker responses that fade faster, so more frequent boosting is needed to maintain any meaningful level of protection. The six-month interval for the second dose aligns with the timeline of waning effectiveness: by that point, even healthy older adults have lost a substantial share of their initial protection.